BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 37284490)

  • 1. Equipping providers to offer novel MPTs: Developing counseling messages for the Dual Prevention Pill in clinical studies and beyond.
    Segal K; Harris DM; Carmone A; Haddad LB; Hadigal S; Hatzold K; Jones C; Lathrop E; Mason J; Mikulich M
    Front Reprod Health; 2023; 5():1155948. PubMed ID: 37284490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of the dual prevention pill for contraception and HIV pre-exposure prophylaxis.
    Milali MP; Resar D; Kaftan D; Campbell J; Olowu A; Edwards D; Platais I; Kim HY; Jenkins S; Bershteyn A
    Front Reprod Health; 2023; 5():1144217. PubMed ID: 37266447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Promise of the Dual Prevention Pill: A Framework for Development and Introduction.
    Friedland BA; Mathur S; Haddad LB
    Front Reprod Health; 2021 Jun; 3():. PubMed ID: 34318291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How might we motivate uptake of the Dual Prevention Pill? Findings from human-centered design research with potential end users, male partners, and healthcare providers.
    Nyagah W; Segal K; Feltham J; Ash A; Major J; Masani M
    Front Reprod Health; 2023; 5():1254953. PubMed ID: 38023531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing the acceptability of, adherence to and preference for a dual prevention pill (DPP) for HIV and pregnancy prevention compared to oral pre-exposure prophylaxis (PrEP) and oral contraception taken separately: protocols for two randomised, controlled, cross-over studies in South Africa and Zimbabwe.
    Friedland BA; Mgodi NM; Palanee-Phillips T; Mathur S; Plagianos MG; Bruce IV; Lansiaux M; Murombedzi C; Musara P; Dandadzi A; Reddy K; Ndlovu N; Zulu SK; Shale LR; Zieman B; Haddad LB
    BMJ Open; 2024 Mar; 14(3):e075381. PubMed ID: 38479746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use and misuse of oral contraceptives: risk indicators for poor pill taking and discontinuation.
    Rosenberg MJ; Waugh MS; Meehan TE
    Contraception; 1995 May; 51(5):283-8. PubMed ID: 7628201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined oral contraceptives: acceptability and effective use.
    Kubba A; Guillebaud J
    Br Med Bull; 1993 Jan; 49(1):140-57. PubMed ID: 8324604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimating the market size for a dual prevention pill: adding contraception to pre-exposure prophylaxis (PrEP) to increase uptake.
    Begg L; Brodsky R; Friedland B; Mathur S; Sailer J; Creasy G
    BMJ Sex Reprod Health; 2021 Jul; 47(3):166-172. PubMed ID: 32737137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. "Being able to do whatever you wanna do as a woman is important:" a qualitative exploration of contraception as a frame of reference for HIV prevention with PrEP.
    Murphy EC; Danvers A; Zamudio AR; Avila K; Proehl M; Gonzalez-Argoti T; Mantell JE; Bauman LJ; Dolan SM
    Reprod Health; 2022 Apr; 19(1):92. PubMed ID: 35392943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Canadian Contraception Consensus (Part 2 of 4).
    Black A; Guilbert E; ; Costescu D; Dunn S; Fisher W; Kives S; Mirosh M; Norman WV; Pymar H; Reid R; Roy G; Varto H; Waddington A; Wagner MS; Whelan AM; ; Ferguson C; Fortin C; Kielly M; Mansouri S; Todd N
    J Obstet Gynaecol Can; 2015 Nov; 37(11):1033-9. PubMed ID: 26629725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Canadian Contraception Consensus (Part 1 of 4).
    Black A; Guilbert E; ; Costescu D; Dunn S; Fisher W; Kives S; Mirosh M; Norman WV; Pymar H; Reid R; Roy G; Varto H; Waddington A; Wagner MS; Whelan AM; ; Ferguson C; Fortin C; Kielly M; Mansouri S; Todd N;
    J Obstet Gynaecol Can; 2015 Oct; 37(10):936-42. PubMed ID: 26606712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. User characteristics and oral contraceptive compliance in Egypt.
    Trottier DA; Potter LS; Taylor BA; Glover LH
    Stud Fam Plann; 1994; 25(5):284-92. PubMed ID: 7871553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Faculty statement from the CEU on a new publication: WHO Selected Practice Recommendations for Contraceptive Use Update. Missed pills: new recommendations.
    Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit
    J Fam Plann Reprod Health Care; 2005 Apr; 31(2):153-5. PubMed ID: 15921560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects on ovarian activity of delaying versus immediately restarting combined oral contraception after missing three pills and taking ulipristal acetate 30 mg.
    Banh C; Rautenberg T; Duijkers I; Borenzstein P; Monteil C; Levy-Gompel D; Klipping C; Scherrer B; Glasier A
    Contraception; 2020 Sep; 102(3):145-151. PubMed ID: 32474062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Instructions for combined pill users.
    Reese M; Hatcher RA
    Contracept Technol Update; 1985 Jan; 6(1):19-20. PubMed ID: 12279914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral contraceptive use and protective behavior after missed pills.
    Oakley D; Potter L; de Leon-Wong E; Visness C
    Fam Plann Perspect; 1997; 29(6):277-9, 287. PubMed ID: 9429874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized trial of the effect of tailored versus standard use of the combined oral contraceptive pill on continuation rates at 1 year.
    Stephenson J; Shawe J; Panicker S; Brima N; Copas A; Sauer U; Wilkinson C; Akintomide H; O'Brien P
    Contraception; 2013 Oct; 88(4):523-31. PubMed ID: 23663917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 150 micrograms desogestrel and either 30 micrograms or 20 micrograms ethinyl oestradiol.
    Akerlund M; Røde A; Westergaard J
    Br J Obstet Gynaecol; 1993 Sep; 100(9):832-8. PubMed ID: 8218004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Compliance, counseling and satisfaction with oral contraceptives: a prospective evaluation.
    Rosenberg MJ; Waugh MS; Burnhill MS
    Fam Plann Perspect; 1998; 30(2):89-92, 104. PubMed ID: 9561874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.